SignalXSignalX

LFVN Lifevantage Corp

Q4 2025 10-Q
Filed: Feb 4, 2026Period ending Dec 31, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Lifevantage Corp Overview

Lifevantage Corp (LFVN) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 4, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q4 2025 10-Q

Risk Factors

  • • No newly added risk factors this quarter; no material changes from most recent 10-K
  • • Continued risk of regulatory compliance impacting business due to multi-level marketing laws and FDA regulations
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$49M

▼ -27.8% YoY▲ +2.9% QoQ

Net Income

$276,000

▼ -89.2% YoY▼ -87.2% QoQ

Gross Margin

74.0%

▼ -653bp YoY▼ -551bp QoQ

Operating Margin

1.0%

▼ -406bp YoY▼ -377bp QoQ

Net Margin

0.6%

▼ -320bp YoY▼ -397bp QoQ

ROE

0.8%

▼ -769bp YoY

Total Assets

$61M

▼ -10.7% YoY

EPS (Diluted)

$0.02

▼ -90.0% YoY▼ -88.2% QoQ

Operating Cash Flow

$3M

▼ -69.7% YoY▲ +221.1% QoQ

Source: XBRL data from Lifevantage Corp Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Lifevantage Corp

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.